Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Inclusion Criteria:

• Adults aged 18 years or older with one of the following newly diagnosed cancers:breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small celllung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma,adenosquamous cell carcinoma, and not otherwise specified).

• Planned treatment with systemic chemotherapy (single or multi-agent, includestargeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1or CTLA-4). If unable to engage participant before treatment starts, enrollment isallowed up to the start of Cycle 2 treatment.

• Participants must be able to comprehend English or Spanish (for survey completion).

• Participants must have a working email address and be must be willing to completesurveys online. This can be completed at home, in the clinic or other location.

• Completion of the confidential Self-Reported Screening Survey and receipt of ascreening result - eligible for enrollment.

• Participant must reside in the United States, officially determined per patientreport on Self-reported Screening Survey

• In the treating provider's opinion, the participant should have a life expectancy of >=6 months. Participants in hospice are not eligible.

Optional Sub-study (available at select sites only):

• Must be willing to participate in both the main study and the sub-study at the WakeForest University Comprehensive Cancer Center (WF CCC) and Virginia CommonwealthUniversity (VCU).

• Must be receiving treatment at the WF CCC and VCU.

• Must be diagnosed with non-small cell lung cancer.

• Must be planning to receive paclitaxel as part of their chemotherapy in conjunctionwith Immune Checkpoint Inhibitor (ICIs) PD-1, PD-L1 or CTLA-4.

Exclusion Criteria:

• Currently enrolled in an interventional supportive treatment trial to manage cancersymptoms.

• Participants with known pregnancy.

• Participant received systemic therapy treatment for prior cancer(s) includingchemotherapy, immunotherapy, targeted therapy, and hormonal therapy.

• Participants enrolled in hospice.

Optional Substudy (available at select sites only):

• Participants with chronic or ongoing steroid or immunomodulatory agents (i.e.,prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoidsas pre-medications for chemotherapy treatment is allowed.

• Participants with a history of HIV, hepatitis B or hepatitis C.